180 Life Sciences Corp. (ATNF)
1.44
-0.10 (-6.49%)
At close: Jan 28, 2025, 1:47 PM
undefined% (undefined)
| Bid | 1.42 |
| Market Cap | 4.56M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 7.98 |
| PE Ratio (ttm) | 0.18 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.45 |
| Volume | 148,829 |
| Avg. Volume (20D) | 475,903 |
| Open | 1.54 |
| Previous Close | 1.54 |
| Day's Range | 1.37 - 1.54 |
| 52-Week Range | 1.16 - 17.75 |
| Beta | undefined |
About ATNF
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials t...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2017
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ATNF
Website https://180lifesciences.com
1 month ago
-24.03%
180 Life Sciences Corp. shares are trading lower a...
Unlock content with
Pro Subscription
3 months ago
+9.79%
180 Life Sciences shares are trading higher after Elray Resources completed a sale of proprietary technology to the company to assist in the launch of an iGaming Blockchain casino.
3 years ago · seekingalpha.com
180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded ATNF with cannabis trailblazer Prof. Raphael Mechoulam, joins the podcast with Dr. Jonathan Rothbard, Chief Science Officer. Focusing on pain...
